Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane

Wai Ho Tang,1 Jeremiah Stitham,1 Scott Gleim,1 Concetta Di Febbo,2 Ettore Porreca,2,3 Cristiano Fava,4 Stefania Tacconelli,3 Marta Capone,3 Virgilio Evangelista,5 Giacomo Levantesi,6 Li Wen,7 Kathleen Martin,1 Pietro Minuz,4 Jeffrey Rade,8 Paola Patrignani,3 and John Hwa1

1Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 2SS. Annunziata Hospital, Chieti, Italy. 3Department of Medicine, Neuroscience and Imaging, and Center of Excellence on Aging, G. d’Annunzio University and “Gabriele d’Annunzio” University Foundation, CeSI, Chieti, Italy. 4Department of Medicine, University of Verona, Verona, Italy. 5Laboratory of Vascular Biology and Pharmacology, Department of Translational Pharmacology Consorzio Mario Negri Sud, Santa Maria Imbaro (Chieti), Italy. 6San Pio da Pietrelcina Hospital, Vasto (Chieti), Italy. 7Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 8Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Diabetes mellitus is associated with platelet hyperactivity, which leads to increased morbidity and mortality from cardiovascular disease. This is coupled with enhanced levels of thromboxane (TX), an eicosanoid that facilitates platelet aggregation. Although intensely studied, the mechanism underlying the relationship among hyperglycemia, TX generation, and platelet hyperactivity remains unclear. We sought to identify key signaling components that connect high levels of glucose to TX generation and to examine their clinical relevance. In human platelets, aldose reductase synergistically modulated platelet response to both hyperglycemia and collagen exposure through a pathway involving ROS/PLCγ2/PKC/α MAPK. In clinical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass surgery), and particularly those with diabetes, urinary levels of a major enzymatic metabolite of TX (11-dehydro-TXB2 [TX-M]) were substantially increased. Elevated TX-M persisted in diabetic patients taking low-dose aspirin (acetylsalicylic acid, ASA), suggesting that such patients may have underlying endothelial damage, collagen exposure, and thrombovascular disease. Thus, our study has identified multiple potential signaling targets for designing combination chemotherapies that could inhibit the synergistic activation of platelets by hyperglycemia and collagen exposure.

Introduction
Accelerated atherosclerosis and microvascular disease contribute to the morbidity and mortality associated with diabetes mellitus (DM) (1–3). Vascular inflammation, endothelial dysfunction associated with hyperglycemia, impaired fibrinolysis, and increased coagulation factors as well as abnormal platelet function are typical for DM, contributing to the increased thrombotic events and development of arteriosclerosis (4). Altered platelet function in DM, including altered adhesion and aggregation, may contribute to the pathogenesis of DM vascular complications by promoting microthrombus formation, contributing to enhanced risk of small vessel occlusions and accelerated atherothrombotic diseases (5, 6). Patients with type 2 DM (T2DM) exhibit platelet hyperreactivity both in vitro and in vivo, coupled with biochemical evidence of persistently increased thromboxane-dependent (TX-dependent) platelet activation (7, 8). Despite many important studies, the mechanism by which platelets transduce glucose levels into enhanced TX generation independently of endothelial and other blood cell–derived factors remains unclear. Similarly, optimal antiplatelet therapy for DM patients remains to be achieved.

Aldose reductase (AR) is the first enzyme of the polyol pathway, and it represents a minor source of glucose utilization, accounting for less than 3% of glucose consumption during euglycemia. However, during hyperglycemia, the activity of AR is substantially increased, representing up to 30% of total glucose consumption, and the abnormal activation of the polyol pathway leads to depletion of reducing equivalents and accumulation of osmotically active polyols (9, 10). Therefore, enhanced utilization of this pathway is well known to contribute to microvascular and macrovascular DM complications by increasing oxidative and osmotic stress. Also, the pharmacological inhibition of AR has been shown to reduce the frequency of polyneuropathy and retinopathy in DM patients (9–11). In fact, it has been shown that human AR expression in transgenic mice accelerates DM atherosclerosis (12), suggesting that AR may play an important role in atherothrombosis. We therefore hypothesized that AR contributes to platelet activation under hyperglycemic conditions and that the signaling mechanism may provide an explanation for the increased risk of atherothrombosis in DM patients.

In the present study, we investigated the role of AR in collagen-induced platelet aggregation and TX biosynthesis under normal-glucose (NG) and high-glucose (HG) conditions and the molecular mechanism by which AR contributes to collagen-induced platelet aggregation and TX generation. Based on these observations, we further pursued 3 case-controlled clinical studies in separate patient populations to support our mechanistic studies and to determine the clinical implications for DM patients. We demonstrate for what we believe is the first time that AR is a key transducer of hyperglycemia through a complex signaling pathway leading to
The effects of glucose on activation were studied in platelets isolated from venous blood of HS. The aggregation in 25 mmol/l glucose was 25% higher than that in 5.5 mmol/l glucose and was attenuated by treatment with 1–10 µmol/l epalrestat (Figure 3, A–C), suggesting that such aggregation was abolished by inhibition of AR. The concentration of epalrestat used in the present study was based on the dose-response curve (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI59291DS1), which is consistent with previous studies (14). To corroborate the spectrophotometric aggregation assays, P selectin, the marker for platelet activation, was analyzed using flow cytometry. As in Figure 2F, collagen-induced P selectin surface expression was enhanced in HG compared with NG (Figure 3, D–F), and epalrestat effectively attenuated the increase in P selectin. In addition, genetic knockdown of AR reduced the P selectin translocation to membrane in collagen-stimulated megakaryocyte (MEG-01) platelet-like particles in NG (Supplemental Figure 2). We further reconfirmed the specificity in response to collagen activation using 2 concentrations of collagen, arachidonic acid (AA), ADP, and thrombin receptor agonist peptide (TRAP) in addition to epalrestat (Supplemental Figure 3).

These results combined suggest that AR plays a central role in collagen-induced platelet aggregation under NG, but particularly under HG, conditions. Supporting these data, we found that HG alone or collagen treatment in NG increased AR activity and that the combination of collagen and HG potentiated this effect (Figure 4A). This increase in activity could not be accounted for by increased AR expression, as collagen treatment (in NG or HG, but not HG alone) induced only a modest increase in AR expression (Figure 4B), which did not correlate with the degree of activation (Figure 4A). Mannitol was used as osmotic control to demonstrate that AR expression is not affected by the increased osmolarity. Thus, collagen and HG synergize in activating AR.

**Inhibition of AR attenuates the phosphorylation of p38α MAPK in human platelets in response to collagen under NG and HG conditions.** In order to identify potential signaling mechanisms by which AR enhances collagen-induced platelet aggregation, we performed a screen using a phosphoproteomic kinase array (R & D Systems) (data not shown). Human platelets induced by 1 µg/ml collagen exhibited a 5-fold increase in p38α phosphorylation, which was markedly attenuated by 10 µmol/l epalrestat. A p38 phosphoproteomic array confirmed that collagen specifically induced phosphorylation of the α isoforms (Figure 5A). The p38α activation by collagen and inhibition by epalrestat in both NG and HG was confirmed by Western blot (Figure 5B). Interestingly, p38α phosphor-
ylation was significantly increased in HG-incubated platelets even in the absence of collagen stimulation (Figure 5B), suggesting that HG incubation may potentiate platelet aggregation via p38α, perhaps through its downstream effector cytosolic phospholipase A2 (cPLA2) (15), leading to TX biosynthesis. Most importantly, collagen-induced platelet aggregation in both NG and HG was reduced by pretreatment with a p38 inhibitor (Figure 5C).

We next aimed to understand the mechanism by which collagen activates p38α. We have demonstrated that collagen activates AR (Figure 4A). As AR can lead to ROS generation, which can regulate p38α (16), we measured oxidative stress production by using specific fluorescent probes. The levels of oxidative stress and superoxide were significantly increased upon collagen-induced platelet aggregation and were even higher in HG compared with NG (Figure 6A). The increases were significantly attenuated by epalrestat, suggesting that AR contributes to oxidative stress in collagen-stimulated platelets. Treatment with 10 mmol/l N-acetyl-cysteine (NAC, ROS scavenger) or 100 μmol/l apocynin (NADPH oxidase inhibitor) also significantly reduced levels of oxidative stress and superoxide. Moreover, HG increased oxidative stress and superoxide production even in the absence of collagen. Notably, NAC and apocynin attenuated collagen-induced platelet aggregation and TX release to an extent similar to that of ARI, indicating that the oxidative stress likely transduced the AR signal (Figure 6, B and C).

Pyocyanin (Pyo), an ROS inducer, served as a positive control in the experiment (Figure 6A).

PLCγ2 is phosphorylated and activated in response to oxidative stress, which is thought to play an important role in platelet...
let activation (17). As shown in Figure 7A, under both NG and HG conditions, the phosphorylation of PLCγ2 was significantly enhanced upon collagen-induced platelet aggregation. Moreover, PLCγ2 phosphorylation was increased under HG conditions even without collagen stimulation. As shown in Figure 7B, treatment with the PLC inhibitor U73122 or the ROS scavenger NAC significantly reduced collagen-induced phosphorylation of p38α MAPK, providing evidence that p38α MAPK activation was regulated by PLCγ2 during collagen-induced platelet aggregation and that this process is associated with oxidative stress. In addition, treatment with another AR inhibitor, quercetin (structurally distinct from epalrestat and with broader specificity), also attenuated collagen-induced phosphorylation of p38α MAPK, further confirming the effect of AR inhibition (Figure 7B). Taken together, these results suggest that AR contributes to collagen-induced platelet activation via oxidative stress–induced tyrosine phosphorylation of PLCγ2.

Inhibition of AR prevents the translocation and phosphorylation of PKC isoforms (α, βII, and δ) in human platelets in response to collagen under NG and HG conditions. PLCγ leads to the generation of diacylglycerol (DAG), which activates the PKC isoforms (18, 19). p38α MAPK

---

**Figure 3**

AR contributes to collagen-induced platelet activation and aggregation. Platelet suspensions were incubated with 5.5 mmol/l glucose (NG) or 25 mmol/l glucose (HG) for 90 minutes in the absence (blue line) or presence of 1 μmol/l (red line) or 10 μmol/l (green line) epalrestat (ARI). Percentage of light transmission was measured in platelet suspensions under (A) NG or (B) HG conditions in response to 1 μg/ml collagen for 5 minutes (n = 5 HS). (C) Quantification of data from 1 μg/ml collagen expressed as aggregation in percentage of light transmission. Data are expressed as mean ± SD (n = 5 HS). ***P < 0.001 and **P < 0.01 compared with the vehicle incubated in 5.5 mM glucose; ###P < 0.001 compared with the vehicle incubated in 25 mM glucose. P-selectin translocation to membrane was assessed by flow cytometry. Representative overlay plots in (D) NG and (E) HG groups in the presence or absence of 10 μmol/l epalrestat were presented as the number of events over the log of associated fluorescence (baseline refers to the group without collagen stimulation). (F) Quantification of data presented as MFI. Data are expressed as mean ± SD (n = 5 HS). ***P < 0.001 compared with the control in 5.5 mM glucose; ###P < 0.001 compared with the control incubated in 25 mM glucose.
is activated downstream of PKC in platelets (20). We therefore studied the effect of AR on PKC isofoms (α, βII, and δ) known to be present in platelets. As shown in Figure 8, A and B, PKCα was highly expressed in the cytosolic fraction in the human platelets under both NG and HG conditions. Upon collagen stimulation, the level of PKCα was increased in the membrane compared with the cytosolic fraction, indicating PKCα translocation to a membrane during platelet aggregation. Inhibition of AR with 10 μmol/l epalrestat prevented collagen-induced translocation of PKCα under both NG and HG conditions. Similar to PKCα, PKCβII and PKCδ were highly expressed in the cytosolic fraction and translocated to the membrane upon collagen-induced platelet aggregation under NG conditions (Figure 8, A, C, and D). However, under HG conditions, the levels of PKCβII and PKCδ were higher in the membrane fraction than in the cytosolic fraction with or without 1 μg/ml collagen, which was attenuated by the treatment with 10 μmol/l epalrestat. The blots were probed with antibodies against Na+/K+ ATPase and GAPDH, which served as the membrane and cytosolic markers, respectively (Figure 8A). Since the subcellular translocation of PKCα, PKCβII, and PKCδ was prevented by AR inhibitor, we next determined whether inhibition of AR prevents the phosphorylation of PKCα, PKC βII, and PKCδ by using phosphospecific antibodies that correlate with kinase activity in total extracts. Consistent with the previous genetic knockout and inhibitor studies on the role of PKC isoforms in platelet aggregation (21, 22), the phosphorylation of different PKC isoforms was in line with the findings in their translocation (Supplemental Figure 4), indicating that PKCα, PKCβII, and PKCδ translocation from cytoplasm to membrane and phosphorylation are required for collagen-induced aggregation. In addition, these results suggest that HG potentiates the activation of PKCβII and PKCδ similarly to the effect of collagen in an AR-dependent manner.

Inhibition of AR blocks TX release in human platelets in response to collagen under NG and HG conditions. cPLA2 generates AA, the substrate for prostanoid synthesis. As cPLA2 is a downstream effector of p38 MAPK in platelets (15, 16), we postulated that AR contributes to collagen-induced aggregation via enhanced TXA2 signaling. We assessed the generation of TXB2 (nonenzymatic metabolite of TXA2) and the levels of TX receptor (TP) in the cytosolic and membrane fractions. During collagen-induced platelet aggregation, TXB2 generation was increased by 10-fold (from ~500 to ~5000 pg/ml) under NG conditions and by nearly 12-fold (from ~650 to ~8000 pg/ml) under HG conditions (Figure 9A). TXB2 required AR activity, as treatment with 10 μmol/l epalrestat significantly reduced the levels of TXB2 released from platelets. The surface expression of TP was also significantly increased, and its expression in the cytosolic fraction was decreased upon collagen-induced platelet aggregation in the HG group but not in the NG group (Figure 9B). Treatment with 10 μmol/l epalrestat significantly abolished the changes in surface expression. ROS also contributed to the TXB2 induction (Figure 6, A and C) and increased platelet activity (Figure 6B). In addition, the HG-induced surface expression of TP was also significantly attenuated by treatment with NAC and apocynin (Figure 9C), supporting a role for ROS. Collectively, these results suggest that AR and oxidative stress are required for hyperglycemia-induced TX generation and TP surface expression.

**Correlation of TXB2 generation with increased platelet aggregation.** We have delineated a pathway in which AR contributes to platelet activation via PLC-dependent activation of p38t, with subsequent TXA2 generation. To validate this pathway, platelet aggregation and TXB2 levels were measured in the presence of U73122 (PLC inhibitor), SB239063 (p38 inhibitor), quercetin, and SQ29548 (TP antagonist). Treatment with PLC and p38 inhibitors attenuated collagen-induced TXB2 release, suggesting that PLCγ2 and its downstream effector, p38t MAPK, contributes to TXB2 release. Moreover, all of these inhibitors reduced platelet aggregation in response to 1 μg/ml collagen. Importantly, treatment with SQ29548 also attenuated collagen-induced platelet aggregation, suggesting an important role for TP in increasing platelet aggregation in NG or HG (Figure 10A). SQ29548 also attenuated collagen-induced TXB2 release, suggesting a potential positive feedback mechanism (Figure 10B). Collectively, our results support a model in which AR activity increases oxidative stress and mediates PLCγ2

**Figure 4**
AR activity is upregulated in collagen-stimulated platelets. (A) Activity of AR in the human platelets in response to 1 μg/ml collagen under NG and HG conditions. Platelet suspensions were incubated with NG or HG for 90 minutes in the presence or absence of 10 μmol/l epalrestat prior to stimulation by 1 μg/ml collagen for 10 minutes. Data are expressed as mean ± SD (n = 5 HS). **P < 0.01, ***P < 0.001, and ****P < 0.005 compared with values incubated in NG alone; ***P < 0.001 compared with values in NG and HG with the addition of 1 μg/ml collagen, respectively. (B) Expression of AR in human platelets in response to 1 μg/ml collagen. Platelet suspensions were incubated with NG or HG for 90 minutes prior to stimulation by 1 μg/ml collagen for 10 minutes, and the total cellular extract was collected for experiments. AR expression was normalized to GAPDH expression. Data are expressed as mean ± SD (n = 5 HS). **P < 0.01 compared with values incubated in NG.
phosphorylation and PKC activation, which leads to p38\(\alpha\) MAPK activation, resulting in collagen-induced TXA\(_2\) generation, TP activation, and aggregation in platelets.

In order to assess the association between TXA\(_2\) generation and increased platelet aggregation, we plotted the percentage of aggregation against the level of released TXB\(_2\). As shown in Figure 10C, a linear relationship with positive slope (\(R^2 = 0.8439;\) slope \(= 6.192\)) occurred between TXB\(_2\) levels and the percentage of aggregation, indicating that increased platelet aggregation is closely correlated with TXA\(_2\) generation in our experimental human models. In addition, this result supports the concept that platelet aggregation increases TXA\(_2\) biosynthesis and increased TXA\(_2\) biosynthesis increases platelet aggregation, leading to an amplifying positive feedback mechanism. This important observation provides an explanation for increased platelet activity during hyperglycemia by AR-dependent induction of TXA\(_2\) generation.

**Increased urinary TX-M levels in patients with deep vein thrombosis (study group 2).** We demonstrated that TXA\(_2\) generation is increased with collagen-induced activation of normal human platelets ex vivo and that acute hyperglycemia further enhanced TXA\(_2\) biosynthesis in vitro. To determine whether glucose levels and collagen-dependent thrombosis induce TXA\(_2\) production in patients, we measured urinary levels of TX-M in a case-controlled study of patients with or without deep vein thrombosis (DVT). DVT is known to be caused in part by endothelial damage and collagen exposure (23). The DVT patients (\(n = 34\)) and controls (\(n = 23\)) were characterized by comparable age, cardiovascular risk factors (cigarette smoking, DM, hypertensive status, lipid levels), BMI, and systemic inflammatory status index (i.e., C-reactive protein [CRP] and fibrinogen). As shown in Figure 11A, there was a statistically significant increase of TX-M in the DVT patients versus controls (for non-DM patients without DVT, the median [with IQR (Q1–Q3)] was 551.5 [436.2 to 600] pg/mg creatinine; for non-DM patients with DVT, it was 942 [657.5 to 1319] pg/mg creatinine). There were 8 DM patients out of 57 total patients, but unfortunately the data on urinary levels of TX-M were only available in 5 DM patients. Interestingly, these few DM patients that were presented had very high TX-M only in the presence of DVT. A further study was necessary in a patient population with a higher incidence of DM to assess the link among DM (hyperglycemia), thrombosis (platelet hyperactivity), and TXA\(_2\) generation in vivo (urinary levels of TX-M).

**Increased urinary levels of TX-M in DM patients with saphenous vein coronary artery bypass graft thrombosis treated with ASA (study group 3).** Because of our interesting DVT findings, we performed another case-controlled study assessing another patient population with a much higher prevalence of DM: a severe coronary artery disease population with coronary artery bypass graft (CABG) thrombosis (Table 1). Not surprisingly, with such severe disease, all patients were on 325 mg daily ASA (to inhibit platelet COX-1–dependent production of TXA\(_2\)) for secondary prevention of further cardiovascular events. The groups were comparable for age and cardiovascular risk factors. As shown in Figure 11B, there were no TX-M differences between DM and non-DM patients without graft occlusion while on ASA (for non-DM patients without CABG thrombosis, the median [with IQR (Q1–Q3)] was 328 pg/mg [233 to 424.5] creatinine; for DM patients without CABG thrombosis, it was 312 pg/mg [226 and 495] creatinine). There was a significant difference between DM and non-DM patients (for non-DM patients with CABG thrombosis, the median [with IQR (Q1–Q3)] was 304 [206 and 450] pg/mg creatinine; for DM patients with CABG thrombosis, it was 466.5 [275 and 718] pg/mg creatinine). This supports our experimental observation that TXA\(_2\) biosynthesis in vivo is enhanced in patients with both thrombosis and DM despite the use

**Figure 5**

AR is required for p38\(\alpha\) MAPK phosphorylation in collagen-stimulated platelets. Platelet suspensions were incubated with NG or HG for 90 minutes in the presence or absence of 10 \(\mu\)mol/l epalrestat prior to stimulation by 1 \(\mu\)g/ml collagen for 10 minutes, and the total extract was harvested for experiments. (A) Phosphorylation of different kinases in collagen-stimulated platelets under NG conditions was assayed by human phosphokinase array kits. Representative results are shown. Co, collagen. (B) Phosphorylation of p38\(\alpha\) MAPK was further measured by Western blot using specific antibody for its phosphorylated form. Data are expressed as mean ± SD (\(n = 5\) HS). \(* * * P < 0.001\) compared with values in NG with the addition of 1 \(\mu\)g/ml collagen; \(* * * P < 0.001\) compared with values in HG with the addition of 1 \(\mu\)g/ml collagen. (C) Platelet suspensions were incubated with NG or HG for 90 minutes in the presence or absence of 50 \(\mu\)mol/l SB2039063 prior to stimulation by 1 \(\mu\)g/ml collagen. Platelet aggregation was presented as the percentage of light transmission and measured in platelet suspensions under NG or HG conditions in response to 1 \(\mu\)g/ml collagen for 5 minutes. Data are expressed as mean ± SD (\(n = 5\) HS). \(* * * P < 0.001\) compared with vehicle incubated in HG. Gluc, glucose.
of ASA. The mechanism for this apparent insensitivity to ASA in the presence of thrombosis and DM required further exploration.

ASA ex vivo does not cause a complete saturation of platelet COX-1 activity. In order to verify whether enhanced generation of TXA$_2$ in vivo was a consequence of inadequate inhibition of platelet COX-1 (ex vivo) by ASA administration, we compared residual generation of TXB$_2$ 12 hours after the last dose of ASA in whole blood allowed to clot for 1 hour at 37°C (serum TXB$_2$), which is an index of maximal capacity of platelets to generate TXB$_2$.

We detected enhanced median values of residual generation of platelet TXB$_2$ in DM patients versus HS; the differences were not statistically significant. However, 12% of DM patients had high-er values of residual TXB$_2$ (i.e., 4 ng/ml) than the upper extreme values of serum TXB$_2$ detected in control subjects after ASA administration. In order to verify whether in these patients higher generation of platelet TXB$_2$ was due to the phenomenon of ASA resistance, which implies that the ASA target, i.e., COX-1, is less sensitive to inactivation by ASA, we assessed residual generation of TXB$_2$ after adding ASA (50 μg/ml) in vitro. As shown in Figure 12, in vitro addition of ASA caused a further significant reduction of TXB$_2$ generation in both DM patients and HS. Importantly, only 2% of patients had residual TXB$_2$ levels higher than 4 ng/ml in DM groups with ASA in vitro. Our results (Figure 12) show that in almost all DM patients, ASA is able to reduce serum TXB$_2$ to a similar extent when in vivo followed by in vitro ASA treatment of patients’ blood is used. Thus, the apparent ASA insensitivity and platelet hyperactivity is, in most cases, not due to ASA resistance, but rather a combination of inadequate ASA bioavailability and increased TX production (and receptor expression) via the AR/ROS pathway.

ASA ex vivo does not cause a complete saturation of platelet COX-1 activity. In order to verify whether enhanced generation of TXA$_2$ in vivo was a consequence of inadequate inhibition of platelet COX-1 (ex vivo) by ASA administration, we compared residual generation of TXB$_2$ 12 hours after the last dose of ASA in whole blood allowed to clot for 1 hour at 37°C (serum TXB$_2$), which is an index of maximal capacity of platelets to generate TXB$_2$.

We detected enhanced median values of residual generation of platelet TXB$_2$ in DM patients versus HS; the differences were not statistically significant. However, 12% of DM patients had high-er values of residual TXB$_2$ (i.e., 4 ng/ml) than the upper extreme values of serum TXB$_2$ detected in control subjects after ASA administration. In order to verify whether in these patients higher generation of platelet TXB$_2$ was due to the phenomenon of ASA resistance, which implies that the ASA target, i.e., COX-1, is less sensitive to inactivation by ASA, we assessed residual generation of TXB$_2$ after adding ASA (50 μg/ml) in vitro. As shown in Figure 12, in vitro addition of ASA caused a further significant reduction of TXB$_2$ generation in both DM patients and HS. Importantly, only 2% of patients had residual TXB$_2$ levels higher than 4 ng/ml in DM groups with ASA in vitro. Our results (Figure 12) show that in almost all DM patients, ASA is able to reduce serum TXB$_2$ to a similar extent when in vivo followed by in vitro ASA treatment of patients’ blood is used. Thus, the apparent ASA insensitivity and platelet hyperactivity is, in most cases, not due to ASA resistance, but rather a combination of inadequate ASA bioavailability and increased TX production (and receptor expression) via the AR/ROS pathway. It is important to point out that the observed residual COX-1 activity is present even after ASA treatment. This COX-1 activity likely converts the increased AA substrate generated from the p38α MAPK/PLA$_2$ activation pathway, leading to enhanced platelet TXA$_2$ generation and increased platelet activation under conditions of acute hyperglycemia and collagen activation.

Analysis of human TP genetic variants in cardiovascular patients. In order to ensure and confirm that the increase in TX levels was not secondary to a dysfunctional or defective TP, genomic DNA from patients and volunteers from the Yale (human platelet signaling studies), Chieti (study groups 1 and 2), and Johns Hopkins (study group 3) studies was sequenced for variants in the TP gene (TBXA2R). No dysfunctional nonsynonymous mutations could account for the observed results (data not shown). This result demonstrates that the difference in TX-M levels between the DM and non-DM patients could not be attributed to structural defects in the human TP (hTP).

Discussion
We set out to discover the mechanism leading to TX release and platelet hyperactivity in DM. We demonstrate for what we
believe is the first time that AR plays a central role in synergistically transducing hyperglycemia and collagen exposure to TX release, increased cell surface TP expression, and enhanced platelet activity. This effect is associated with ROS generation and the activation of PLCγ2, PKCβII, PKCδ, and p38α MAPK (Figure 13).

Our clinical studies support these results, as increased TXA2 generation in vivo, particularly in DM patients, reflected underlying thrombovascular disease (DVT and CABG thrombosis). These mechanistic insights may explain in part the poor prognosis observed with patients presenting with hyperglycemia and acute coronary syndrome (24–30). Enhanced platelet activity due to a combination of hyperglycemia and collagen exposure may predispose to further thromboembolic disease.

Complex regulatory pathway required for the synergistic effects of glucose on collagen-stimulated aggregation. The enhanced utilization of the AR pathway during hyperglycemia is well known to contribute to disease in many tissues, including microvascular and macrovascular complications, polyneuropathy, and retinopathy in DM patients (10, 11). Surprisingly, its role and relationship to TX release and platelet hyperactivity has been unexplored. We now demonstrate that AR plays a critical role in transducing collagen signaling in platelet aggregation and that this is further enhanced in conditions of hyperglycemia. Our mechanistic studies are supported by a recent study using 2D difference gel electrophoresis and mass spectrometry, which demonstrated that the expression of AR was significantly increased in the activated human platelets after stimulation of the GPVI receptor (14). The binding of collagen to GPVI results in receptor clustering and phosphorylation of the tyrosine kinase Syk and the activation of PLCγ (31). In platelets, many PLC isoforms have been identified, and evidence suggests that the signaling through collagen-induced aggregation is mediated by the receptor-bound tyrosine kinase Syk and the activation of PLCγ (32, 33). We have now demonstrated that PLCγ2 phosphorylation is greatly increased in the glucose-treated platelets and collagen-induced platelet aggregation and that PLC inhibition using U73122 effectively prevented collagen-induced TXB2 generation and aggregation, suggesting that PLCγ2 phosphorylation is required for collagen-induced platelet aggregation. Looking further downstream (Figure 13), in HG- and collagen-stimulated platelets, PKCα, PKCβII, and PKCδ were translocated from cytosol to membrane, with concomitant increase in their phosphorylated forms, thus supporting a role of PKCα, PKCβII, and PKCδ in this process. These findings are also supported by previous studies that demonstrate PKCα, PKCβII, and PKCδ as playing a crucial role in collagen-induced platelet aggregation (21, 22). Thus, a complex web of signaling components is involved in platelet activation upon exposure to collagen and hyperglycemia (Figure 13). Our study unifies many of the platelet-dependent signaling compo-

Figure 7
AR is required for PLC phosphorylation in collagen-stimulated platelets. (A) Platelet suspensions were incubated with NG or HG for 90 minutes in the presence of 10 μmol/l epalrestat prior to stimulation by 1 μmol/l collagen for 10 minutes, and the total extract was harvested for experiments. Data are expressed as mean ± SD (n = 5 HS). ***P < 0.001 and **P < 0.01 compared with values incubated in NG alone; ****P < 0.001 compared with values in NG with the addition of 1 μmol/l collagen; **P < 0.01 compared with values in HG with the addition of 1 μmol/l collagen. p-PLCγ2, phospho-PLCγ2. (B) Inhibition of the upstream pathway of p38α MAPK attenuated its phosphorylation in collagen-stimulated platelets. Platelet suspensions were incubated with NG or HG for 90 minutes in the presence of 5 μmol/l U73122, 1 mmol/l NAC, and 10 μmol/l quercetin prior to stimulation by 1 μmol/l collagen for 10 minutes, and the total extract was harvested for experiments. Data are expressed as mean ± SD (n = 5 HS). ***P < 0.001 and *P < 0.05 compared with values incubated in NG or HG alone, respectively; ****P < 0.001 compared with values in NG or HG with the addition of 1 μmol/l collagen, respectively. p-p38α, phospho-p38α.
Oxidative stress plays an important role in TX-induced platelet hyperactivity. Glucose flux through AR is well recognized to generate oxidative stress by several mechanisms, including NADPH depletion, decreasing glutathione (GSH) levels (NADPH is the cofactor for GSH reductase that regenerates GSH from GSSG), and increasing advanced glycation end products, generating ROS (10). Previous studies have demonstrated that TXA₂ biosynthesis is upregulated by oxidant formation (e.g., hydrogen peroxide) during platelet aggregation (34–36). We and others (16, 20) have demonstrated that hyperglycemia increases oxidative stress in platelets. We show that this potentiates p38α MAPK/cPLA₂ signaling, which catalyzes AA release, producing TXA₂. Interestingly, ROS derived from platelet activation also plays an important role in signaling upon collagen-induced platelet aggregation. Free radical species act as secondary messengers that increase cytosolic Ca²⁺ during the initial phase of platelet activation processes, and PKC is involved in receptor-mediated ROS production in platelets (36). Previous studies also showed that ROS formation is involved in collagen-induced platelet aggregation, which is dependent on AA release and its metabolism (34); thus, ROS may be needed for platelet activation (37). Indeed, our studies demonstrate that oxidative stress is significantly increased in collagen-stimulated platelets, and inhibition of AR partly attenuated collagen-induced oxidative stress, supporting an important role for AR-exacerbated oxidative stress in collagen-dependent signaling. Furthermore, our current study and those of others have now demonstrated oxidative stress–induced stabilization and relocation of TP to the cell surface (38, 39).
lead to this cascade of hyperactivation, thrombosis, and hyperactivation. As described, it may be that the trigger is endothelial damage (collagen exposure) and that, when combined with hyperglycemia-induced oxidative stress, ROS initiates an amplifying cycle of increased PLC/PKC/p38α MAPK signaling, TXA2 generation, and platelet hyperactivation. Interestingly, previous animal studies demonstrated that enhanced platelet aggregation and TX synthesis may be detected within days of triggering DM with streptozotocin, suggesting that alterations in platelets and endothelial damage (with collagen exposure) may occur early in the DM state (8). Extrather factors such as NO and prostacyclin are keys to breaking such a cycle; however, there is growing evidence that these naturally occurring antiaggregatory agents are reduced in DM (40).

As our DM patients were on ASA, it was necessary to determine why TX production remained elevated, particularly in the patients from study group 1 (Figure 1). We offer 2 major reasons based upon our results. First, as described, hyperglycemia synergizes with collagen stimulation in platelets to activate the AR-dependent polyol pathway, which increases oxidative stress. The oxidative stress can increase TXA2 production by potentiating p38α MAPK/cPLA2 signaling, thus providing more substrates (AA) for uninhibited COX-1 to produce TXA2. Additionally, hyperglycemia- and collagen-induced oxidative stress from the AR-dependent polyol pathway can also lead to enhanced expression of TP, increasing the potency of any circulating TXA2. When combined with reduced bioavailability, as observed with the 100 mg (enteric coated) daily usage patients, and thus incomplete inhibition of COX-1 (Figure 12), the combination results in a marked increase in TXA2 over that in control patients (Figure 1). Such differences are less marked when patients are on 325 mg ASA (study group 3, Reduction in Graft Occlusion Rates [RIGOR] group; Figure 11B). Thus AR-dependent signaling pathways upon glucose/collagen platelet activation may provide, in part, an explanation for apparent ASA insensitivity in DM patients and may shed light on the concept of ASA insensitivity in general.

**AR inhibitors as antiplatelet therapy?** Our study highlights the importance of concurrent clinical studies to substantiate in vitro findings. DM patients with high urinary levels of TX-M despite ASA treatment may have underlying occult endothelial damage and thrombovascular disease. We propose that in the context of vascular damage with collagen exposure and HG, unacetylated platelet COX-1 despite ASA may participate in TXA2 biosynthesis on a background of increased p38α MAPK–induced PLAc activity and thus enhanced AA substrate. Higher doses of ASA or low-dose ASA given twice daily may translate into an appropriate suppression of TXA2 in vivo (assessing the levels of urinary TX-M). Alternatively, the addition of AR inhibitors should be considered to mitigate enhanced TXA2 generation despite ASA treatment in

---

**Figure 9**

AR is involved in TX signaling in platelets. Role of AR in (A) TX generation and (B) surface expression of TP in collagen-stimulated platelets. Platelet suspensions were incubated with NG or HG for 90 minutes in the presence or absence of 10 μmol/l epalrestat prior to stimulation with 1 μg/ml collagen for 10 minutes. Levels of TXB2 were assayed in the supernatant. Expression of TP was assessed in the membrane and cytosolic fractions. Expression of TP in cytosolic and membrane fraction was normalized to GAPDH and Na+/K+ ATPase expression, respectively. Data are expressed as mean ± SD (n = 5 HS). **P < 0.001 compared with values incubated in NG alone; **P < 0.001 and ***P < 0.01 compared with values in NG with the addition of 1 μg/ml collagen; **P < 0.001 and ***P < 0.01 compared with values in HG with the addition of 1 μg/ml collagen. (C) Expression of TP was assessed in the membrane and cytosolic fractions. Data are expressed as mean ± SD (n = 5 HS). **P < 0.001 compared with values incubated in HG alone; **P < 0.001 compared with values in HG with the addition of 1 μg/ml collagen.
DM patients. Epalrestat used in the present study is an AR inhibitor that is approved in Japan to prevent or slow the progression of DM neuropathy (41, 42). Our study using human platelets demonstrates that hyperglycemia-induced TX signaling and hyperaggregability were effectively attenuated by treatment with epalrestat. The use of AR inhibitors may be particularly effective against postprandial hyperglycemia, which is associated with enhanced lipid peroxidation and platelet activation in early T2DM (43) and increased platelet aggregation in DM patients with microangiopathy (44). The addition of AR inhibitors may be a new therapeutic option to prevent thrombotic events in DM patients.

Limitations of the present studies. There are a number of limitations to our current studies. Foremost, the sizes of our studies are relatively small. Further larger studies assessing both arterial and venous thrombosis in the setting of hyperglycemia and DM are required to corroborate our results. Although we have focused on the platelet-dependent mechanism, this is a reductionist approach, as many other factors from blood cells, the endothelium, and vascular smooth muscle cells clearly play an important role in the development of the DM platelet response. Our studies also focus on acute increases in glucose without addressing the effects of chronic increases. Moreover, there are many other important components to the DM response (e.g., protein glycation) besides AR that likely contribute to increased platelet activity. The final picture is likely to be far more complex, as not all studies in DM patients have demonstrated consistent increases in TX production (45). Despite these limitations, our study provides strong evidence for a multitargeted approach and the foundation and justification for further clinical therapeutic trials to prevent atherothrombotic disease arising from platelet hyperactivity in patients with DM.

Summary. It is currently a subject of debate whether enhanced platelet activity associated with DM is a cause (thrombosis, e.g., plaque rupture) or consequence (metabolic disturbance) of disease. Our studies indicate that both of these are true. The combination of hyperglycemia during collagen activation leads to a positive feedback cycle of release of platelet TX and enhanced platelet aggregation (cause and consequence). Moreover, we demonstrate that AR leading to enhanced ROS production and TX generation plays a major role in this synergistic response. Our findings support the use of higher doses of ASA; however, inhibition of vascular prostacyclin biosynthesis makes this choice inadvisable. The foundation for antiplatelet therapy in DM patients may very well be a combination of ASA with AR inhibitors (and/or TX inhibitors) for both primary and secondary prevention of cardiovascular events.

Methods

Drugs and inhibitors. The AR inhibitor epalrestat and the NADPH oxidase inhibitor apocynin were purchased from Santa Cruz Biotechnology Inc. The antioxidant NAC was from Fisher Scientific. The p38 MAPK inhibitor SB239063 and the phospholipase C inhibitor U73122 were from Calbio-
Venous blood was drawn from volunteers in the RIGOR study. Platelet suspensions were incubated with α-isothiocyanate–conjugated, AK4; Biolegend, as described previously (48), for patients with CABG thrombosis (RIGOR patients), the level of urinary TX metabolite was measured in DM patients with or without CABG thrombosis (n = 28 and n = 75, respectively) compared with non-DM patients with or without CABG thrombosis (n = 68 and n = 120, respectively). All the patients were treated with ASA (325 mg once daily) upon discharge from surgery as described in Methods. Data are expressed as median with IQR.

**Preparation of human platelets.** Venous blood was drawn from volunteers at Yale University Medical School, who were free from medication known to interfere with platelet function. Platelet-rich plasma (PRP) was prepared from blood (27 ml) that was drawn by venipuncture into 3 ml of 3.8% trisodium citrate (w/v). PRP was obtained by centrifugation of blood at 250 g at 25°C for 15 minutes, and the platelet count in the PRP was estimated by an automated cell counter. Platelet-poor plasma (PPP) was obtained by centrifugation of the rest of the blood at 1400 g at 25°C for 10 minutes. The PRP was adjusted with PPP to 2 × 10^8 platelets/ml suspension. For the washed platelets, PRP was obtained by centrifugation at 250 g for 15 minutes, and platelets were sedimented at 1000 g for 15 minutes and then resuspended in washing buffer (103 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgCl₂, 5 mmol/l glucose, 36 mmol/l citric acid, pH 6.5) containing 3.5 mg/ml BSA (Sigma-Aldrich). After sedimentation, the platelets were washed twice in this buffer and resuspended at 2 × 10^8 platelets/ml in the buffer composed of 5 mmol/l HEPES, 137 mmol/l NaCl, 2 mmol/l KCl, 1 mmol/l MgCl₂, 12 mmol/l NaHCO₃, 0.3 mmol/l NaH₂PO₄ and 5.5 mmol/l glucose, pH 7.4, containing 3.5 mg/ml BSA (46).

**Measurement of platelet aggregation.** Platelet suspensions were incubated with 5.5 or 25 mmol/l glucose in the presence or absence of 1 or 10 μmol/l epalrestat for 90 minutes prior to stimulation by 1 μg/ml collagen for 10 minutes. The samples were then washed and fixed in 1% paraformaldehyde for 1 hour at 4°C. The fixed platelets were then washed and labeled with saturating concentrations of monoclonal antibody for 1 hour. All the samples were analyzed on a flow cytometer (FACSCalibur). Platelets were identified and gated by their characteristic forward- and side-scatter properties, and 20,000 platelets were analyzed from each sample.

**Western blotting.** Platelets were homogenized in the lysis buffer (25 mmol/l Tris HCl, pH 7.6, 150 mmol/l NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), with the addition of 0.1% protease inhibitor and 0.1% phosphatase inhibitor (Thermo Scientific). The supernatant was collected after centrifugation at 15,700 g for 15 minutes at 4°C. The samples were loaded in 4x SDS-Laemmli sample buffers and boiled for 10 minutes. Equal amounts of total extracts were subjected to SDS-PAGE. The proteins were transferred to nitrocellulose membrane and probed with the indicated antibodies, and the antigen-antibody complex was detected by enhanced chemiluminescence reagents (Thermo Scientific). Primary antibodies against the following proteins were diluted and used according to the manufacturer’s instructions: AR (sc-17732; Santa Cruz Biotechnology Inc.), PKCα (sc-208; Santa Cruz Biotechnology Inc.) and its phosphorylated form (sc-136018, Thr638; Santa Cruz Biotechnology Inc.).

**Table 1**

<table>
<thead>
<tr>
<th>Cardiovascular risk factors for the populations studied</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Male/female</td>
</tr>
<tr>
<td>Median age (range)</td>
</tr>
<tr>
<td>BMI</td>
</tr>
<tr>
<td>Dyslipidemia</td>
</tr>
<tr>
<td>DM</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Smokers</td>
</tr>
</tbody>
</table>

The Journal of Clinical Investigation  http://www.jci.org  Volume 121  Number 11  November 2011  4473
PKCβ II (NB110-57358; Novus Biologicals) and its phosphorylated form (NSB964, Thr641; Novus Biologicals), PKCδ (2058; Cell Signaling Technology) and its phosphorylated form (9376, Ser643; Cell Signaling Technology), PLCγ2 (NB110-66669; Novus Biologicals) and its phosphorylated form (NB110-57424, Tyr1217; Novus Biologicals), p38α MAPK (9212; Cell Signaling Technology) and its phosphorylated form (AF869, T180/Y182; R&D Systems), and TP (NBP1-40198; Novus Biologicals). Secondary antibodies against rabbit and mouse IgG (Thermo Scientific) were diluted to 1:5000 before use. The membrane was reprobed with antibodies against Na+/K+ -ATPase (NB300-147; Novus Biologicals), a plasma membrane marker, and GAPDH (sc-20357; Santa Cruz Biotechnology), a cytoplasmic marker, for normalization.

Measurement of AR activity. The platelets were homogenized and centrifuged as for Western blot analysis. To determine the AR activity, a spectrophotometry measurement was used as described previously (49).

Human phosphokinase array. The human phosphokinase array was performed according to the manufacturer’s instructions (R&D Systems). Briefly, the lysates were diluted to 200 μg/ml using the specific array buffer, mixed with a cocktail of biotinylated detection antibodies, and incubated overnight with nitrocellulose membranes spotted with capture and control antibodies. The signals for the amount of phosphorylated proteins bound were measured by the chemiluminescent detection method.

Subcellular fractionation. Platelets were sedimented by centrifugation at 2500 g for 5 minutes. The membrane and cytosolic fractions of total extracts were separated using the subcellular protein fractionation kit (Thermo Scientific). Briefly, the platelets were incubated with cytoplasmic extraction buffer for 10 minutes at 4°C and then centrifuged at 500 g for 5 minutes. The supernatant was harvested as the cytoplasmic extract. The pellet was reconstituted with the ice-cold membrane extraction buffer and incubated for 10 minutes at 4°C. After incubation, it was then centrifuged at 3000 g for 5 minutes, and the supernatant was harvested as the membrane extract. Aliquots (60–100 μg protein) of the soluble and the membrane fractions were separated by SDS-PAGE and subjected to Western blot

Figure 12
Effect of in vitro administration of ASA on the residual TXB2 generation in HS and DM patients. Serum TXB2 levels, markers of platelet COX-1 activity, were assessed in HS (n = 14) and DM (n = 102) patients with low-dose ASA (100 mg/day). Residual generation of TXB2 was assessed in whole blood allowed to clot for 1 hour at 37°C 12 hours after the last dose of ASA. Data are expressed as median with IQR. **P < 0.01 and *P < 0.05 compared with values in the corresponding group without ASA in vitro.

PKCβII (NB110-57358; Novus Biologicals) and its phosphorylated form (NSB964, Thr641; Novus Biologicals), PKCδ (2058; Cell Signaling Technology) and its phosphorylated form (9376, Ser643; Cell Signaling Technology), PLCγ2 (NB110-66669; Novus Biologicals) and its phosphorylated form (NB110-57424, Tyr1217; Novus Biologicals), p38α MAPK (9212; Cell Signaling Technology) and its phosphorylated form (AF869, T180/Y182; R&D Systems), and TP (NBP1-40198; Novus Biologicals). Secondary antibodies against rabbit and mouse IgG (Thermo Scientific) were diluted to 1:5000 before use. The membrane was reprobed with antibodies against Na+/K+ -ATPase (NB300-147; Novus Biologicals), a plasma membrane marker, and GAPDH (sc-20357; Santa Cruz Biotechnology), a cytoplasmic marker, for normalization.

Measurement of AR activity. The platelets were homogenized and centrifuged as for Western blot analysis. To determine the AR activity, a spectrophotometry measurement was used as described previously (49).

Human phosphokinase array. The human phosphokinase array was performed according to the manufacturer’s instructions (R&D Systems). Briefly, the lysates were diluted to 200 μg/ml using the specific array buffer, mixed with a cocktail of biotinylated detection antibodies, and incubated overnight with nitrocellulose membranes spotted with capture and control antibodies. The signals for the amount of phosphorylated proteins bound were measured by the chemiluminescent detection method.

Subcellular fractionation. Platelets were sedimented by centrifugation at 2500 g for 5 minutes. The membrane and cytosolic fractions of total extracts were separated using the subcellular protein fractionation kit (Thermo Scientific). Briefly, the platelets were incubated with cytoplasmic extraction buffer for 10 minutes at 4°C and then centrifuged at 500 g for 5 minutes. The supernatant was harvested as the cytoplasmic extract. The pellet was reconstituted with the ice-cold membrane extraction buffer and incubated for 10 minutes at 4°C. After incubation, it was then centrifuged at 3000 g for 5 minutes, and the supernatant was harvested as the membrane extract. Aliquots (60–100 μg protein) of the soluble and the membrane fractions were separated by SDS-PAGE and subjected to Western blot

Figure 13
Proposed mechanism for hyperglycemia-induced platelet hyperactivity through TX signaling mediated by the AR pathway. Hyperglycemia synergizes with collagen stimulation in platelets to activate the AR-dependent polyol pathway, leading to increased ROS production (via GSH depletion and NADH oxidase [Nox]). Excessive ROS can increase TXA2 production by potentiating PLCγ2/PKC/p38α MAPK signaling, thus providing more arachidonic acid substrate for COX-1 and TXA2 synthase (TS) to produce TXA2, leading to platelet hyperactivity. The oxidative stress can also lead to enhanced surface expression of TP, which increases the potency of circulating TXA2.
Platelets were sedimented by centrifugation at 2500 g for 5 minutes, and the supernatant was harvested for the measurement of TX levels. Since TXA2 is rapidly hydrolyzed into TxB2, the levels of TxB2 were measured using the TxB2 EIA kit according to the manufacturer’s ELISA instructions (Cayman Chemical).

Measurement of oxidative stress and superoxide level. The oxidative stress and superoxide levels were measured by a commercial kit according to the manufacturer’s instructions (Total ROS/Superoxide Detection Kit; Enzo Life Sciences). Platelets were sedimented by centrifugation at 400 g for 5 minutes and then washed. The washed platelets were incubated with 1 μmol/L ROS/Superoxide Detection Mix for 60 minutes at 37°C in the presence or absence of 1 μg/ml collagen. Changes in fluorescence intensity were measured using a microplate fluorescence reader (BioTek) at excitation/emission wavelengths of 488/520 nm (oxidative stress) and 550/610 nm (superoxide).

Genetic knockdown of AR in human megakaryocytes culture. The megakaryocytes (MEG-01 cells) (CRL-2021; ATCC) were cultured in RPMI medium. Cells were transfected with 0.1 or 0.3 mM AR siRNA (sc-37119; Santa Cruz Biotechnology Inc.) using electroporation kits (Lonza). After 48 hours of incubation with RPMI medium containing 5.5 mM glucose, the P selectin translocation to membrane was assessed by flow cytometry in response to 1 μg/ml collagen.

We planned to pursue in vivo mouse studies to confirm our human platelet studies; however, there was significantly reduced AR in mouse platelets (Supplemental Figure 5) and additional indications that mouse platelet collagen activation is not ASA sensitive (50, 51). We therefore elected to directly pursue human clinical studies.

Protocol for initial patient study (study group 1). All protocols were approved by the respective Institutional Review Boards. Patients with T2DM (n = 102) were recruited from the Hospital Policlinico G.B. Rossi (Verona, Italy) and San Pio da Pietrelcina Hospital. Exclusion criteria included concurrent cancer, inflammatory disorder, immunological disorder, surgery or major trauma in the previous month, or use of NSAIDs or corticosteroids in the previous month. The DM population was on enteric-coated ASA (100 mg) for at least 7 consecutive days (all were chronically treated with low-dose ASA for cardiovascular event prevention). After recruitment, the patients received a standard oral dose of 100 mg for 7 days at 8:00 pm. Timed urine collection (12 hours from 8:00 pm to 8:00 am) was performed on the seventh day of treatment. The HS recruited were from the staff of Hospital Policlinico G.B. Rossi and had normal ECG and echocardiograms and no evidence of atherosclerosis by carotid artery sonography. The HS were all treated with ASA (100 mg) daily also for 7 days. Urine collection (12 hours from 8:00 pm to 8:00 am) was performed on the seventh day of treatment.

Protocol for studies on DVT (study group 2) and saphenous vein graft occlusion (study group 3). For the DVT clinical study (study group 2), all patients with DVT of the lower extremities were diagnosed with duplex ultrasound scanning or peripheral venous angiography. Exclusion criteria were concurrent infection, inflammatory condition or cancer, prolonged immobilization (i.e., lasting more than 7 days) from any cause, recent trauma or surgery (i.e., within the previous 3 months), pregnancy, recent childbirth, or the use of oral contraceptives at the time of the assessment. All patients were not on ASA treatment for at least 2 weeks prior to enrollment. Baseline cardiovascular characteristics were comparable between patients and controls in the DVT subjects, including age, cardiovascular risk factors (cigarette smoking, DM, hypertensive status, and lipid levels), BMI, and systemic inflammatory status index (i.e., CRP and fibrinogen). Urinary TX metabolite TX-M was measured by a previously validated radioimmunoassay technique (52) and expressed as a ratio of urinary creatinine.

The RIGOR study is a multicenter study that investigated the effects of platelet factor 4 and heparin-induced antibody during saphenous vein graft (SVG) occlusion (study group 3). Patients 18 years or older undergoing their first CABG surgery with SVGs were eligible for enrollment. All patients were administered ASA (300 to 325 mg) 24 hours prior to bypass surgery and at discharge (325 mg ASA, 1 pill daily). Pill counts were performed at each postoperative encounter. SVG patency was assessed by multidetector computed tomography coronary angiography at 6 months. Two blinded reviewers classified the patency with 98% concordance. A third reviewer adjudicated any discordance. At 6 months, urinary TX-M was also measured along with platelet aggregometry. Details of the original studies and principle findings have been reported in previous studies (53, 54). The cardio-vascular risk factors for study group 2 (DVT) and study group 3 (RIGOR) are summarized in Table 1.

Statistics. All data were expressed as mean ± SEM or mean ± SD where appropriate. One-way ANOVA, followed by Neuman-Keuls multiple comparison test, was used to assess the difference between the mean values of different groups within the same study. For the clinical studies in which results were not a normal distribution, median and IQR (Q1–Q3) were presented graphically. Nonparametric analysis (Mann-Whitney U test) was performed. P < 0.05 was considered significant.

Study approval. The approval for the human studies was authorized at the respective institutions by the following review boards: study group 1: Ethical Committee of the “Azienda Ospedaliera di Verona,” Verona, Italy; study group 2: Comitato di etica per la ricerca biomedica dell’Università degli studi “G. D’Annunzio”; study group 3: Johns Hopkins University Institutional Review Board; ex vivo and in vitro studies: Yale University School of Medicine Human Investigational Committee. All patients provided written informed consent prior to entry into the studies.

Acknowledgments

This work was supported in part by the NIH (RO1 HL074190 to J. Hwa), an American Heart Association Established Investigator Award (to J. Hwa), the Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2006 to P. Patrignani), a Fondazione Carichieti-Fondazione Negri Sud ONLUS (to V. Evangelista), and by the European Community Sixth Framework Programme (Eicosanox grant LSMH-CT-2004-005033 to P. Patrignani). We also thank Todd Mackenzie (Statistician, Department of Medicine, Dartmouth Medical School) for his statistical advice and analysis, and Stefano Maranini for her technical assistance.

Received for publication June 1, 2011, and accepted in revised form September 7, 2011.

Address correspondence to: John Hwa, Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, Cardiovascular Research Center, 300 George Street, Rm. 759H, New Haven, Connecticut 06511, USA. Phone: 203.737.5583; Fax: 203.737.6118; E-mail: John.Hwa@yale.edu


